[HTML][HTML] Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
AB El-Khoueiry, J Clarke, T Neff, T Crossman… - British journal of …, 2023 - nature.com
Background GSK3368715, a first-in-class, reversible inhibitor of type I protein
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
AB El-Khoueiry, J Clarke, T Neff, T Crossman… - British Journal of …, 2023 - europepmc.org
Background GSK3368715, a first-in-class, reversible inhibitor of type I protein
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
[HTML][HTML] Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
AB El-Khoueiry, J Clarke, T Neff… - British Journal of …, 2023 - ncbi.nlm.nih.gov
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
AB El-Khoueiry, J Clarke, T Neff… - British journal …, 2023 - mdanderson.elsevierpure.com
Background: GSK3368715, a first-in-class, reversible inhibitor of type I protein
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
AB El-Khoueiry, J Clarke, T Neff… - British journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background GSK3368715, a first-in-class, reversible inhibitor of type I protein
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
AB El-Khoueiry, J Clarke, T Neff, T Crossman… - British Journal of …, 2023 - europepmc.org
Background GSK3368715, a first-in-class, reversible inhibitor of type I protein
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …
methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This …